

Question on Notice

No. 831

Asked on 26 June 2025

MR S KNUTH ASKED MINISTER FOR HEALTH AND AMBULANCE SERVICES (HON T NICHOLLS)—

QUESTION

With reference to the UK Cass review on the affirmation model used to treat Gender Dysphoria, and a recent media report that a former judge who helped deliver the decision allowing parents to approve puberty blockers for their children without court oversight has stated that advanced medical evidence had shown it was ‘pretty clear’ the treatment was risky—

Will the Minister immediately suspend the affirmation model currently used by Queensland Health?

ANSWER

On 28 January 2025, a Health Service Directive was issued to specify a restriction on the provision of stage 1 (puberty blocking hormone) treatment and stage 2 (gender affirming hormone) treatment to children and adolescents under 18 years of age with Gender Dysphoria in Queensland Health facilities.

The Queensland Government commissioned an independent review (the Review), led by Professor Ruth Vine, with the support of a panel of expert reviewers has commenced with a final report due to the Director-General of Queensland Health by 30 November 2025.

The Review will consider the evidence and ethical considerations and provide policy advice to the Queensland Government regarding the use of Stage 1 and Stage 2 hormones for children and adolescents with gender dysphoria in Queensland's public hospital system.